Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | PRNP | P04156 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071205 | 0.89 | ALDH1A1 (0.41) | PRNPNPSR1RXFP1TSHRGAA | |
| SCHEMBL6071015 | 0.89 | L3MBTL1 (0.40) | GAAALDH1A1HSD17B10S1PR3CYP1A2 | |
| SCHEMBL4858585 | 0.80 | KCNA5 (0.49) | TACR3KCNA5CA12CA7CA9 | |
| SCHEMBL6071175 | 0.79 | TACR3 (0.45) | TACR3ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6070967 | 0.75 | L3MBTL1 (0.48) | NPSR1ADORA2ACYP1A2 | |
| SCHEMBL6070725 | 0.74 | ALDH1A1 (0.51) | TACR3KCNA5CA12CA7CA9 | |
| SCHEMBL8119650 | 0.73 | SIGMAR1 (0.53) | KCNA5CA12CA7CA9CA14 | |
| SCHEMBL4851208 | 0.73 | SIGMAR1 (0.53) | KCNA5CA12CA7CA9CA14 | |
| SCHEMBL20577929 | 0.73 | SIGMAR1 (0.53) | KCNA5CA12CA7CA9CA14 | |
| SCHEMBL6071535 | 0.71 | SMN1; SMN2 (0.43) | PRNPNPSR1RXFP1USP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2006-01-19 | — | — | US | disclosed |
| EP-1397136-A1 | HETEROCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2004-03-17 | — | — | EP | disclosed |
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2003-06-19 | — | — | US | disclosed |
| WO-2002096424-A1 | HETEREOCYCLIC BETA-AMINOACIDS AND THEIR USE AS ANTI-EPILEPTOGENIC AGENTS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114441-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | CA3, GAP43, SLC1A2 | TACR3 993/4885PRNP 2536/4885NPSR1 246/4885 |
| US-20060014752-A1 | Heterocyclic anti-epileptogenic agents and methods of use thereof | GAP43, GABRE, CA3 | TACR3 1311/4885PRNP 2330/4885NPSR1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.